AlphaThera

AlphaThera is a private, commercial-stage biotech company providing a proprietary platform for site-specific antibody conjugation. Founded in 2017, the company offers a broad portfolio of off-the-shelf and custom conjugation reagents and services, positioning itself as a tool provider for researchers and developers in diagnostics and biotherapeutics. Its product line spans from research tools like fluorescent conjugates to critical components for Antibody-Drug Conjugate (ADC) development, indicating a business model blending platform technology with service and product revenue. The company appears to be in a revenue-generating phase, selling directly to end-users and through a distributor network.

oYo-Link® site-specific antibody conjugation platform enabling controlled attachment of payloads (dyes, enzymes, oligonucleotides, drugs) to antibodies via a proprietary, potentially photo-activated chemistry.

AlphaThera competes in the broad antibody reagents market dominated by giants like Thermo Fisher Scientific and Abcam. In site-specific conjugation, it faces competition from specialized players like Syndivia, Abzena, and the conjugation service arms of CDMOs (Contract Development and Manufacturing Organizations). Its differentiation lies in the breadth of its off-the-shelf product catalog and focus on user-friendly, fast protocols.